Rare Hematology

Global Rare Hematology Market to Reach US$25.3 Billion by 2030

The global market for Rare Hematology estimated at US$18.1 Billion in the year 2023, is expected to reach US$25.3 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2023-2030. Plasma Derived Factors, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$18.2 Billion by the end of the analysis period. Growth in the Recombinant Factors segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.9 Billion While China is Forecast to Grow at 4.6% CAGR

The Rare Hematology market in the U.S. is estimated at US$4.9 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.0 Billion by the year 2030 trailing a CAGR of 4.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Rare Hematology Market - Key Trends & Drivers Summarized

What Is The Rare Hematology Market and Why Is It Gaining Momentum in Healthcare?

The Rare Hematology market focuses on the diagnosis, treatment, and management of rare blood disorders, which include conditions such as hemophilia, sickle cell disease, thalassemia, paroxysmal nocturnal hemoglobinuria (PNH), and various types of anemia. These diseases are classified as rare because they affect a small percentage of the global population, typically less than 1 in 2,000 individuals. Although the patient population for each rare hematologic condition is relatively small, the cumulative impact of these diseases on healthcare systems is significant due to their chronic nature, complex management requirements, and the high cost of treatments. Traditionally, patients with rare hematologic conditions have faced limited treatment options and low levels of research investment. However, recent advancements in genomics, biotechnology, and personalized medicine are changing this scenario, leading to a surge in research and development activities aimed at discovering novel therapies and improving patient outcomes. As a result, the Rare Hematology market is gaining momentum, driven by increasing awareness, supportive policies, and the introduction of cutting-edge treatments that are reshaping the management of these challenging conditions.

The rise of patient advocacy groups and increased collaboration between healthcare providers, pharmaceutical companies, and regulatory bodies have also contributed to the growth of the Rare Hematology market. Organizations such as the National Organization for Rare Disorders (NORD) and the European Hematology Association (EHA) have been instrumental in advocating for more research funding, better access to treatments, and enhanced patient care. These efforts have spurred pharmaceutical companies to invest in the development of orphan drugs—medications designed to treat rare conditions—despite the smaller market size. Governments around the world have introduced various incentives, including market exclusivity, tax credits, and fast-track approval processes, to encourage the development of these specialized treatments. As a result, the Rare Hematology market has seen a steady influx of new therapeutic options, ranging from gene therapies and monoclonal antibodies to advanced biologics. With the advent of these innovative solutions, healthcare providers are better equipped to manage rare hematologic disorders, improving the quality of life for patients who previously had limited or no treatment options.

How Are Technological Advancements Transforming The Treatment Landscape Of Rare Hematologic Disorders?

Technological advancements have played a transformative role in the development of therapies for rare hematologic disorders, revolutionizing the way these diseases are diagnosed and treated. One of the most groundbreaking innovations in this field is the advent of gene therapy. Gene therapies target the underlying genetic mutations responsible for many rare blood disorders, offering the potential for long-term or even curative treatments. For example, in the treatment of hemophilia, gene therapies aim to introduce a functional copy of the defective gene, enabling patients to produce the necessary clotting factors naturally, thereby reducing or eliminating the need for regular factor replacement therapy. Similarly, gene-editing technologies such as CRISPR-Cas9 are being explored as potential treatments for sickle cell disease and beta-thalassemia, with early clinical trials showing promising results. These technologies have the potential to transform the treatment paradigm for rare hematologic disorders, offering hope for patients who have historically relied on symptomatic treatments.

In addition to gene therapy, advances in biologics and targeted therapies are expanding the range of treatment options available for rare hematologic conditions. Monoclonal antibodies, for instance, have been developed to target specific pathways or proteins involved in disease progression, offering a more precise approach to treatment with fewer side effects. For conditions like PNH, targeted therapies such as complement inhibitors have been introduced, which effectively reduce hemolysis and the risk of thrombosis, significantly improving patient outcomes. Furthermore, the integration of personalized medicine into rare hematology is enabling healthcare providers to tailor treatments based on individual genetic profiles, ensuring a higher degree of efficacy and safety. Diagnostic technologies are also evolving, with next-generation sequencing (NGS) and high-throughput screening methods making it possible to identify rare genetic mutations with greater accuracy and speed. These technological advancements are not only enhancing the precision of diagnoses but also facilitating earlier detection and intervention, which are crucial for managing rare hematologic disorders more effectively.

What Factors Are Driving The Adoption Of New Treatments In The Rare Hematology Market?

Several factors are contributing to the increased adoption of new treatments in the Rare Hematology market, including the growing prevalence of rare blood disorders, advancements in medical research, and favorable regulatory frameworks. The rising incidence of rare hematologic conditions is partly due to improved diagnostic capabilities, which have led to higher detection rates and more accurate classification of these diseases. With more patients being accurately diagnosed, there is a greater demand for innovative therapies that go beyond conventional treatments. At the same time, advancements in medical research, particularly in the fields of genomics and biotechnology, are enabling the development of more effective and targeted therapies. The success of these therapies in clinical trials has spurred pharmaceutical companies to invest heavily in rare hematology, leading to an increase in the availability of new and improved treatment options for patients.

Another key driver of treatment adoption is the supportive regulatory environment. Recognizing the unique challenges associated with developing therapies for rare diseases, regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established special designations like Orphan Drug Status and Breakthrough Therapy Designation. These programs provide incentives such as extended market exclusivity, expedited review processes, and reduced regulatory fees, making it more attractive for companies to pursue drug development in the rare hematology space. Additionally, the growing influence of patient advocacy groups has led to increased awareness and better access to information about available treatments, empowering patients and their families to seek out specialized care and novel therapies. As a result, there is a rising acceptance of these new treatments, especially among patient populations that previously had limited or no therapeutic options. The combination of these factors is driving higher adoption rates and expanding the reach of new therapies within the Rare Hematology market.

What Is Driving The Growth Of The Global Rare Hematology Market?

The growth in the global Rare Hematology market is driven by several factors, including the increased focus on rare disease research, advancements in therapeutic technologies, and evolving healthcare policies. One of the primary growth drivers is the rising investment in research and development by pharmaceutical and biotechnology companies. Encouraged by favorable regulatory incentives and growing patient demand, companies are dedicating substantial resources to the discovery and development of innovative therapies for rare blood disorders. This has led to a steady pipeline of new treatments, ranging from gene therapies and enzyme replacements to next-generation biologics and small molecule drugs. The market is also benefiting from technological innovations that are enabling more effective disease modeling, drug screening, and clinical trials, thereby accelerating the development process and bringing new therapies to market more quickly.

Evolving healthcare policies are another crucial driver of market growth. Many countries have introduced national rare disease plans or policies aimed at improving the diagnosis, treatment, and care of patients with rare diseases, including hematologic conditions. These policies often include initiatives to increase research funding, support the development of specialized care centers, and improve patient access to advanced therapies. Furthermore, collaborations between academia, industry, and patient organizations are fostering a more collaborative research environment, accelerating the pace of innovation in the field. Another growth driver is the increasing prevalence of rare hematologic conditions, which is creating a larger patient pool in need of specialized treatments. Improved awareness and better diagnostic capabilities are contributing to higher diagnosis rates, which in turn are driving demand for targeted therapies and comprehensive care solutions. As these factors converge, the global Rare Hematology market is poised for continued growth, supported by a strong innovation pipeline, enhanced regulatory frameworks, and an ever-increasing focus on improving patient outcomes and quality of life.

Select Competitors (Total 42 Featured) -
  • Alexion Pharmaceuticals, Inc.
  • Bayer Healthcare AG
  • CSL Behring
  • Novo Nordisk A/S
  • PRA Health Sciences
  • Shire PLC
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Rare Hematology – Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Growing Awareness of Rare Blood Disorders Spurs Growth of the Rare Hematology Market
Rising Investment in Orphan Drug Development Strengthens Business Case for Rare Hematology Therapeutics
Advancements in Gene and Cell Therapy Propel Innovation in Rare Hematology Treatments
Development of Innovative Therapeutics for Hemophilia Drives Market Demand
Focus on Expanding Treatment Options for Sickle Cell Disease Accelerates Market Growth
Development of Novel Biomarkers for Blood Disorders Expands Scope of Rare Hematology Treatments
Emergence of Stem Cell Therapies Bodes Well for Market Growth
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Rare Hematology Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Rare Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Rare Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Rare Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Plasma Derived Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Plasma Derived Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Plasma Derived Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Recombinant Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Recombinant Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Recombinant Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Adult (18+) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Adult (18+) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Adult (18+) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Pediatric (0-17) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Pediatric (0-17) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Pediatric (0-17) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 17: USA Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 18: USA Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: USA 16-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2014, 2024 & 2030
TABLE 20: USA Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: USA Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: USA 16-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2014, 2024 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: Canada 16-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2014, 2024 & 2030
TABLE 26: Canada Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: Canada Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Canada 16-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2014, 2024 & 2030
JAPAN
Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 29: Japan Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: Japan Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: Japan 16-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2014, 2024 & 2030
TABLE 32: Japan Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 33: Japan Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Japan 16-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2014, 2024 & 2030
CHINA
Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 35: China Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: China Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: China 16-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2014, 2024 & 2030
TABLE 38: China Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: China Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: China 16-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2014, 2024 & 2030
EUROPE
Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 41: Europe Recent Past, Current & Future Analysis for Rare Hematology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 42: Europe Historic Review for Rare Hematology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Europe 16-Year Perspective for Rare Hematology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 44: Europe Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Europe Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Europe 16-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2014, 2024 & 2030
TABLE 47: Europe Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Europe Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Europe 16-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2014, 2024 & 2030
FRANCE
Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 50: France Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: France Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: France 16-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2014, 2024 & 2030
TABLE 53: France Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: France Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: France 16-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2014, 2024 & 2030
GERMANY
Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 56: Germany Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Germany Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Germany 16-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2014, 2024 & 2030
TABLE 59: Germany Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Germany Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Germany 16-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2014, 2024 & 2030
ITALY
TABLE 62: Italy Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Italy Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Italy 16-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2014, 2024 & 2030
TABLE 65: Italy Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Italy Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Italy 16-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2014, 2024 & 2030
UNITED KINGDOM
Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 68: UK Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: UK Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: UK 16-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2014, 2024 & 2030
TABLE 71: UK Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: UK Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: UK 16-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Rest of Europe Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Rest of Europe 16-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2014, 2024 & 2030
TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Rest of Europe Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Rest of Europe 16-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Rare Hematology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Asia-Pacific Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Asia-Pacific 16-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2014, 2024 & 2030
TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Asia-Pacific Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Asia-Pacific 16-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 86: Rest of World Recent Past, Current & Future Analysis for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Rest of World Historic Review for Rare Hematology by Product Type - Plasma Derived Factors and Recombinant Factors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Rest of World 16-Year Perspective for Rare Hematology by Product Type - Percentage Breakdown of Value Sales for Plasma Derived Factors and Recombinant Factors for the Years 2014, 2024 & 2030
TABLE 89: Rest of World Recent Past, Current & Future Analysis for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Rest of World Historic Review for Rare Hematology by Age Group - Adult (18+) and Pediatric (0-17) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Rest of World 16-Year Perspective for Rare Hematology by Age Group - Percentage Breakdown of Value Sales for Adult (18+) and Pediatric (0-17) for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings